Author pages are created from data sourced from our academic publisher partnerships and public sources.
Tiotropium Respimat Inhaler and the Risk of Death in COPD
Tiotropium Respimat inhaler and the risk of death in COPD.
- R. Wise, A. Anzueto, +9 authors Peter Calverley
- The New England journal of medicine
- 16 October 2013
BACKGROUND Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in… Expand
The Respimat® Development Story: Patient-Centered Innovation
AbstractThe Respimat® Soft Mist™ Inhaler represents a unique delivery system for respiratory medications, using an innovative concept with major technological advancements made during prototype… Expand
A Handling Study to Assess Use of the Respimat® Soft Mist™ Inhaler in Children Under 5 Years Old
- W. Kamin, M. Frank, Sabine Kattenbeck, P. Moroni-Zentgraf, H. Wachtel, S. Zielen
- Journal of aerosol medicine and pulmonary drug…
- 1 October 2015
Abstract Background: Respimat® Soft Mist™ Inhaler (SMI) is a hand-held device that generates an aerosol with a high, fine-particle fraction, enabling efficient lung deposition. The study objective… Expand
Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials.
- F. Ratjen, P. Koker, +5 authors J. Elborn
- Journal of cystic fibrosis : official journal of…
- 1 September 2015
BACKGROUND Tiotropium Respimat improved lung function in a phase 2 trial in patients with cystic fibrosis (CF). We investigated its efficacy and safety in a phase 3 trial, including a pre-specified… Expand
Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis.
- A. Sharma, D. Geller, +8 authors P. Koker
- Pulmonary pharmacology & therapeutics
- 1 December 2014
Tiotropium is the first bronchodilator to be studied systematically in cystic fibrosis (CF). We investigated whether any intrinsic or extrinsic factors affected pharmacokinetic (PK) parameters of… Expand
61 Tiotropium Respimat in cystic fibrosis: Efficacy and safety results of phase III randomized placebo-controlled trial
F. Ratjen1, P. Koker2, D. Geller3, B. Langellier-Cocteaux4, F. Le Maulf4, S. Kattenbeck5, P. Moroni-Zentgraf6, J.S. Elborn7. 1The Hospital of Sick Children, Toronto, Canada; 2Boehringer Ingelheim… Expand
64 Tiotropium in cystic fibrosis: Pooled analysis of phase II and III randomized, controlled trials
The Tiotropium Safety and Performance in Respimat (TIOSPIR) trial: Bronchodilator efficacy in a spirometry substudy
A Handling Study to Assess the Use of the Respimat® Soft Mist™ Inhaler in Children Aged 4–12 Years
IntroductionThe Respimat® Soft Mist™ Inhaler (SMI) is a hand-held device that generates an aerosol with a high fine-particle fraction, enabling efficient lung deposition. Inhalation therapy for… Expand